Cryoglobulins are immunoglobulins that precipitate in vitro at temperatures less than 37° C
and produce organ damage through two main pathways: vascular sludging (hyperviscosity …

Hepatitis C virus (HCV) infected patients are known to be at risk of developing liver
complications ie cirrhosis and liver cancer. However, the risks of morbidity and mortality are …

Objectives: To develop European League Against Rheumatism (EULAR) recommendations
for the management of small and medium vessel vasculitis. Methods: An expert group …

Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet
responses without continued dosing are limited. Whereas complete responses (CRs) to B …

Objective To conduct a long‐term, prospective, randomized controlled trial evaluating
rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis …

BACKGROUND: Mixed cryoglobulinemia (MC) is a systemic vasculitis secondary to
circulating immune complex deposition in the small vessels. In the overwhelming majority of …

The detection of a monoclonal immunoglobulin in serum or urine usually raises concerns
about the size of the underlying B-cell-derived clone and possible systemic effects caused …

B-cell-targeted therapy for autoimmune disease emerged from theoretical proposition to
practical reality between 1997 and 1998, with the availability of the B-cell-depleting …

Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-
Hodgkin's B-cell lymphoma. Recently it has also been used in the treatment of several …

After more than 10 years of use, rituximab has proven to be remarkably safe. However,
accumulated evidence now suggests that under some circumstances it may significantly …